Cargando…

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape

BACKGROUND: The diversity and plasticity behind ER+/PR−/HER2− breast cancer have not been widely explored. It is essential to identify heterogeneous microenvironment phenotypes and investigate specific genomic events driving the formation of these phenotypes. METHODS: Based on the immune-related gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Peiling, An, Rui, Yu, Shibo, He, Jianjun, Zhang, Huimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454077/
https://www.ncbi.nlm.nih.gov/pubmed/34544424
http://dx.doi.org/10.1186/s12967-021-03076-x
_version_ 1784570414456897536
author Xie, Peiling
An, Rui
Yu, Shibo
He, Jianjun
Zhang, Huimin
author_facet Xie, Peiling
An, Rui
Yu, Shibo
He, Jianjun
Zhang, Huimin
author_sort Xie, Peiling
collection PubMed
description BACKGROUND: The diversity and plasticity behind ER+/PR−/HER2− breast cancer have not been widely explored. It is essential to identify heterogeneous microenvironment phenotypes and investigate specific genomic events driving the formation of these phenotypes. METHODS: Based on the immune-related gene expression profiles of 411 ER+/PR−/HER2− breast cancers in the METABRIC cohort, we used consensus clustering to identify heterogeneous immune subtypes and assessed their reproducibility in an independent meta-cohort including 135 patients collected from GEO database. We further analyzed the differences of cellular and molecular characteristics, and potential immune escape mechanism among immune subtypes. In addition, we constructed a transcriptional trajectory to visualize the distribution of individual patient. RESULTS: Our analysis identified and validated five reproducible immune subtypes with distinct cellular and molecular characteristics, potential immune escape mechanisms, genomic drivers, as well as clinical outcomes. An immune-cold subtype, with the least amount of lymphocyte infiltration, had a poorer prognosis. By contrast, an immune-hot subtype, which demonstrated the highest infiltration of CD8+ T cells, DCs and NK cells, and elevated IFN-γ response, had a comparatively favorable prognosis. Other subtypes showed more diverse gene expression and immune infiltration patterns with distinct clinical outcomes. Finally, our analysis revealed a complex immune landscape consisting of both discrete cluster and continuous spectrum. CONCLUSION: Overall, this study revealed five heterogeneous immune subtypes among ER+/PR–/HER2− breast cancer, also provided important implications for clinical translations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-03076-x.
format Online
Article
Text
id pubmed-8454077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84540772021-09-21 A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape Xie, Peiling An, Rui Yu, Shibo He, Jianjun Zhang, Huimin J Transl Med Research BACKGROUND: The diversity and plasticity behind ER+/PR−/HER2− breast cancer have not been widely explored. It is essential to identify heterogeneous microenvironment phenotypes and investigate specific genomic events driving the formation of these phenotypes. METHODS: Based on the immune-related gene expression profiles of 411 ER+/PR−/HER2− breast cancers in the METABRIC cohort, we used consensus clustering to identify heterogeneous immune subtypes and assessed their reproducibility in an independent meta-cohort including 135 patients collected from GEO database. We further analyzed the differences of cellular and molecular characteristics, and potential immune escape mechanism among immune subtypes. In addition, we constructed a transcriptional trajectory to visualize the distribution of individual patient. RESULTS: Our analysis identified and validated five reproducible immune subtypes with distinct cellular and molecular characteristics, potential immune escape mechanisms, genomic drivers, as well as clinical outcomes. An immune-cold subtype, with the least amount of lymphocyte infiltration, had a poorer prognosis. By contrast, an immune-hot subtype, which demonstrated the highest infiltration of CD8+ T cells, DCs and NK cells, and elevated IFN-γ response, had a comparatively favorable prognosis. Other subtypes showed more diverse gene expression and immune infiltration patterns with distinct clinical outcomes. Finally, our analysis revealed a complex immune landscape consisting of both discrete cluster and continuous spectrum. CONCLUSION: Overall, this study revealed five heterogeneous immune subtypes among ER+/PR–/HER2− breast cancer, also provided important implications for clinical translations. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-03076-x. BioMed Central 2021-09-20 /pmc/articles/PMC8454077/ /pubmed/34544424 http://dx.doi.org/10.1186/s12967-021-03076-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xie, Peiling
An, Rui
Yu, Shibo
He, Jianjun
Zhang, Huimin
A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
title A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
title_full A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
title_fullStr A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
title_full_unstemmed A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
title_short A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
title_sort novel immune subtype classification of er-positive, pr-negative and her2-negative breast cancer based on the genomic and transcriptomic landscape
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454077/
https://www.ncbi.nlm.nih.gov/pubmed/34544424
http://dx.doi.org/10.1186/s12967-021-03076-x
work_keys_str_mv AT xiepeiling anovelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape
AT anrui anovelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape
AT yushibo anovelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape
AT hejianjun anovelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape
AT zhanghuimin anovelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape
AT xiepeiling novelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape
AT anrui novelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape
AT yushibo novelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape
AT hejianjun novelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape
AT zhanghuimin novelimmunesubtypeclassificationoferpositiveprnegativeandher2negativebreastcancerbasedonthegenomicandtranscriptomiclandscape